Hovingh GK, et al. - This study was designed to assess long-term efficacy, safety, and tolerability of evolocumab in patients with heterozygous familial hypercholesterolemia (HeFH) during open-label extension trials. Findings demonstrated that long-term dosing of evolocumab with standard of care (SOC) was safe, well tolerated and afforded significant LDL-C reductions during 48 weeks of follow-up.